Abstract
Aim
The main goal in Crohn´s disease (CD) is a sustained suppression of inflammatory activity associated with mucosa healing in endoscopic evaluation. During clinical routine, there are small numbers of good markers to monitor inflammatory activity under treatment. We postulated that Oral 67Gallium Citrate Scintigraphy is able to mark inflammatory disease in mucosa and deep inflammation in CD, when used in oral form.
Objective
Measure the accuracy of Oral 67Gallium Citrate Scintigraphy in intestinal inflammatory activity of Crohn´s disease.
Patients and methods
In a prospective consecutive cross-sectional study from January 2018 to June 2019, the ileocolonic region of 32 patients with CD were studied by dividing into four regions of interest (ROI) from the ileum to the rectum. A total of 128 intestinal segments were analyzed in cluster data. Accuracy values of Oral 67Gallium Scintigraphy and colonoscopy tests were evaluated with the histological reference test. Values of the respective receiver operating characteristic (ROC) curves were obtained and compared. The reliability between the tests was evaluated by Kappa statistical with the segment-level analyses using variance adjustments. All statistical analyses were performed with a test significance level of 0.05.
Results
The study population included 32 patients with CD (10 men, 22 women; average age 39 years). Disease time was five years on average. Anti-TNFs treatment was found in 71%. The most found phenotype of the Montreal classification was L3. Differences in ROC curves for colonoscopy (0.94) and Oral 67Ga Scintigraphy (0.96) did not show significant value (p = 0.32). The sensitivity of scintigraphy to detect intestinal inflammatory activity in CD was 64%, specificity of 96% and accuracy of 84%. A high agreement was found between oral scintigraphy and histological measurements with kappa = 0.64.
Conclusions
Oral 67Ga Scintigraphy had similar accuracy and agreement compared to colonoscopy in the identification of inflammatory activity in Crohn´s Disease. This new approach may be useful and less invasive for long term follow-ups.
Similar content being viewed by others
References
Mazzuoli S, Guglielmi FW, Antonelli E, Salemme M, Bassotti G, Villanacci V. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis. 2013;45(12):969–77.
Maconi G, Armuzzi A. Beyond remission and mucosal healing in Crohn's disease. Exploring the deep with cross sectional imaging. Dig Liver Dis. 2017;49(5):457–8.
Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, et al. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. J Crohns Colitis. 2013;7(9):730–5.
Froslie KF, Jahnsen J, Moum BA, Vatn MH, Group I. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133(2):412–22.
Tajra JB, Calegaro JU, de Paula AP, Bachour D, Silveira D, Lozi M, et al. Correlation and concordance measures between clinical, endoscopic and histological scores activity in Crohn's disease under treatment. Scand J Gastroenterol. 2019;54(4):441–5.
Gong W, Guo K, Zheng T, Fang M, Xie H, Li W, et al. Correlation between endoscopic and histological validated scoring indices in Crohn's disease. Dig Liver Dis. 2019;51(6):812–7.
Castiglione F, Mainenti P, Testa A, Imperatore N, De Palma GD, Maurea S, et al. Cross-sectional evaluation of transmural healing in patients with Crohn's disease on maintenance treatment with anti-TNF alpha agents. Dig Liver Dis. 2017;49(5):484–9.
Goetz M. Endoscopic surveillance in inflammatory bowel disease. Visc Med. 2018;34(1):66–71.
Asli IN, Ehsani MJ, Javadi H, Semnani S, Tabib SM, Assadi M. Comparison of three with six regions of interest analyses in patients with idiopathic constipation undertaking colon transit scintigraphy using 67Ga-citrate. Eur Rev Med Pharmacol Sci. 2013;17(1):69–74.
Becker W, Meller J. The role of nuclear medicine in infection and inflammation. Lancet Infect Dis. 2001;1(5):326–33.
Bellen JC, Chatterton BE, Penglis S, Tsopelas C. Gallium-67 complexes as radioactive markers to assess gástrico and colonic transit. J Nucl Med. 1995;36:513–7.
Joseph U, Jhingran SG, Johnson PC. Gallium-67 imaging and Crohn's disease. J Nucl Med. 1979;20(8):903–4.
Othman MF, Mitry NR, Lewington VJ, Blower PJ, Terry SY. Re-assessing gallium-67 as a therapeutic radionuclide. Nucl Med Biol. 2017;46:12–8.
Baumgart DCSW. Crohn`s disease. Lancet. 2012;380:1590–605.
Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3–25.
Siegel JA, Wu RK, Knight LC, Zelac RE, Stern HS, Malmud LS. Radiation dose estimates for oral agents used in upper gastrointestinal disease. J Nucl Med. 1983;24:835–7.
Lai EJ, Calderwood AH, Doros G, Fix OK, Jacobson BC. The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc. 2009;69(3 Pt 2):620–5.
Khanna R, Zou G, D'Haens G, Rutgeerts P, McDonald JW, Daperno M, et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut. 2016;65(7):1119–25.
Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7(10):827–51.
Naini BV, Cortina G. A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Hum Pathol. 2012;43(12):2187–96.
Joseph NE WC. Pathology of Inflammatory Bowel Disease. Crohn´s Disease and Ulcerative Colitis. I. Canada: Springer; 2017.
Genders TS, Spronk S, Stijnen T, Steyerberg EW, Lesaffre E, Hunink MG. Methods for calculating sensitivity and specificity of clustered data: a tutorial. Radiology. 2012;265(3):910–6.
Rao JN, Scott AJ. A simple method for the analysis of clustered binary data. Biometrics. 1992;48(2):577–85.
Yang Z, Zhou M. Kappa statistic for clustered matched-pair data. Stat Med. 2014;33(15):2612–33.
Gilletta C, Lewin M, Bourrier A, Nion-Larmurier I, Rajca S, Beaugerie L, et al. Changes in the Lémann Index values during the first years of Crohn's disease. Clin Gastroenterol Hepatol. 2015;13(9):1633–40.
Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Löfberg R, Modigliani R, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122(2):512–30.
Zittan E, Kelly OB, Kirsch R, Milgrom R, Burns J, Nguyen GC, et al. Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn's disease. Inflamm Bowel Dis. 2016;22(3):623–30.
Zakeri N, Pollok RC. Diagnostic imaging and radiation exposure in inflammatory bowel disease. World J Gastroenterol. 2016;22(7):2165–78.
Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427–34.
de Bruyn M, Arijs I, De Hertogh G, Ferrante M, Van Assche G, Rutgeerts P, et al. Serum neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate marker for mucosal healing in patients with Crohn's disease. J Crohns Colitis. 2015;9(12):1079–87.
de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13(1):13–27.
Funding
This work was supported by the Base Hospital Institute through the Endoscopic Center and Pathology Department.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None of the authors have any financial interests or conflict of interest to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tajra, J.B.M., Calegaro, J.U., de Paula, A.P. et al. Accuracy of Oral 67Gallium Citrate Scintigraphy in assessment of inflammatory activity of Crohn’s disease. Ann Nucl Med 34, 263–271 (2020). https://doi.org/10.1007/s12149-020-01447-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-020-01447-w